Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Clinical role
Post-acquisition prostate MRI review and analysis with semi-automatic contouring; the user edits, reviews, and confirms the prostate outline and performs the other annotations and measurements.
Images and patients
MRI · Prostate
Key limitation
Keep in mind: Not fully automatic and not a lesion-segmentation tool. Prostate volume is the semi-automatic measurement and requires user review; other annotations and measurements are manual. The user must confirm the final result, decisions must not rely on it alone, and the packet's validation is limited to Siemens 3T Vida/Skyra, specified T2 slice thickness, and tested patients aged 55 years and above.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Prostate Input: DICOM-compatible multiparametric prostate MRI data including T2-weighted, DWI, ADC, and DCE sequences; FDA performance data used Siemens 3T Vida and Skyra systems and T2 slice thicknesses of 3.5-5 mm, with patients aged 55 years and above.
Who uses it?Intended users: Trained radiologists and urologists
What does the software produce?Output: Semi-automatic prostate outline and total prostate volume; overlaid images, registered and combined multiparametric views, user-defined ROIs, manually entered PSA density, PI-RADS and other manual annotations, DWI/DCE graphs, and a structured report.
What is its most important limitation?Key limitation: Not fully automatic and not a lesion-segmentation tool. Prostate volume is the semi-automatic measurement and requires user review; other annotations and measurements are manual. The user must confirm the final result, decisions must not rely on it alone, and the packet's validation is limited to Siemens 3T Vida/Skyra, specified T2 slice thickness, and tested patients aged 55 years and above.
Clinical takeaway. Clinical role: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Evidence takeaway. Evidence from the reviewed source record: FDA K233196 reports stand-alone prostate-region segmentation and reader-performance testing. The stand-alone clinical test used 114 T2 prostate MR images with ground truth from three expert radiologists; overall Dice was 0.928 (95% CI 0.925-0.931) and Hausdorff distance was 2.171 (95% CI 1.097-3.245). Reader Dice improvements with the algorithm were 0.156, 0.011, and 0.008 for the three radiologists. The FDA summary also describes Korea, US, and ProstateX test datasets and a mean-Dice criterion of 0.894.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Post-acquisition prostate MRI review and analysis with semi-automatic contouring; the user edits, reviews, and confirms the prostate outline and performs the other annotations and measurements.
DICOM-compatible multiparametric prostate MRI data including T2-weighted, DWI, ADC, and DCE sequences; FDA performance data used Siemens 3T Vida and Skyra systems and T2 slice thicknesses of 3.5-5 mm, with patients aged 55 years and above.
Semi-automatic prostate outline and total prostate volume; overlaid images, registered and combined multiparametric views, user-defined ROIs, manually entered PSA density, PI-RADS and other manual annotations, DWI/DCE graphs, and a structured report.
Not fully automatic and not a lesion-segmentation tool. Prostate volume is the semi-automatic measurement and requires user review; other annotations and measurements are manual. The user must confirm the final result, decisions must not rely on it alone, and the packet's validation is limited to Siemens 3T Vida/Skyra, specified T2 slice thickness, and tested patients aged 55 years and above.
FDA K233196 reports stand-alone prostate-region segmentation and reader-performance testing. The stand-alone clinical test used 114 T2 prostate MR images with ground truth from three expert radiologists; overall Dice was 0.928 (95% CI 0.925-0.931) and Hausdorff distance was 2.171 (95% CI 1.097-3.245). Reader Dice improvements with the algorithm were 0.156, 0.011, and 0.008 for the three radiologists. The FDA summary also describes Korea, US, and ProstateX test datasets and a mean-Dice criterion of 0.894.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K233196 reports stand-alone prostate-region segmentation and reader-performance testing. The stand-alone clinical test used 114 T2 prostate MR images with ground truth from three expert radiologists; overall Dice was 0.928 (95% CI 0.925-0.931) and Hausdorff distance was 2.171 (95% CI 1.097-3.245). Reader Dice improvements with the algorithm were 0.156, 0.011, and 0.008 for the three radiologists. The FDA summary also describes Korea, US, and ProstateX test datasets and a mean-Dice criterion of 0.894.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Medihub Prostate regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233196
Samplen=114
IndependenceIndependence not established
K233196
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233196. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compatible multiparametric prostate MRI data including T2-weighted, DWI, ADC, and DCE sequences; FDA performance data used Siemens 3T Vida and Skyra systems and T2 slice thicknesses of 3.5-5 mm, with patients aged 55 years and above.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM-compatible MRI input, browser access, and export or transfer of results are described. The packet does not establish a specific current PACS, RIS, EHR, interface version, or deployment configuration.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes MEDIHUB PROSTATE as software that can be accessed through a web browser and runs on off-the-shelf hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "It can be accessed through a web browser, and provides the following main features:" … "MEDIHUB PROSTATE is both software applications running on off-the-shelve hardware.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Semi-automatic prostate outline and total prostate volume; overlaid images, registered and combined multiparametric views, user-defined ROIs, manually entered PSA density, PI-RADS and other manual annotations, DWI/DCE graphs, and a structured report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Semi-automatic prostate outline and total prostate volume; overlaid images, registered and combined multiparametric views, user-defined ROIs, manually entered PSA density, PI-RADS and other manual annotations, DWI/DCE graphs, and a structured report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes MEDIHUB PROSTATE as software that can be accessed through a web browser and runs on off-the-shelf hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "It can be accessed through a web browser, and provides the following main features:" … "MEDIHUB PROSTATE is both software applications running on off-the-shelve hardware.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
DICOM-compatible MRI input, browser access, and export or transfer of results are described. The packet does not establish a specific current PACS, RIS, EHR, interface version, or deployment configuration.
JLK's security page states a security program aligned with SOC 2 and HIPAA, AWS hosting in US regions with VPC isolation, TLS 1.2+ in transit, AES-256 at rest with KMS, role-based access, mandatory MFA for internal users, annual external penetration testing and security training. It states alignment, not an attestation report. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Medihub Prostate; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K233196 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Authorized purpose: PROView is an aiding tool for the clinicians to review multi-parametric prostate MR images following PI-RADS guidelines. It displays acquired and reformatted data for visualization and provides tools for assessment of the prostate gland volume and findings analysis in patients with known or suspected prostate lesions. Measurements and associated scoring are included in a report for communication to referring physicians.
Authorized purpose: Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.
Authorized purpose: RSI-MRI+ is indicated for use as automatic post-acquisition image processing software for analysis of diffusion-weighted and anatomical magnetic resonance imaging data. RSI-MRI+ is intended for automatic fusion of derived diffusion-weighted MRI data with anatomical T2-weighted MR images. RSI-MRI+ is additionally intended to provide automatic prostate segmentation, quantification, and reporting of derived image metrics.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.